Research output per year
Research output per year
Search results
-
2024
Artificial Intelligence Technologies for Assessing Skin Lesions for Referral on the Urgent Suspected Cancer Pathway to Detect Benign Lesions and Reduce Secondary Care Specialist Appointments: Early Value Assessment
Walton, M. J., Llewellyn, A., Uphoff, N., Lord, J., Harden, M., Hodgson, R. & Simmonds, M. C., 28 Aug 2024, National Institute for Health and Care Excellence.Research output: Book/Report › Commissioned report
-
Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia
Deng, J., Corbett, M. S., Uphoff, N., Lord, J., Fulbright, H., Griffin, S., Rothery, C. & Hodgson, R., 2 Aug 2024, National Institute for Health and Care Excellence.Research output: Book/Report › Commissioned report
-
Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer (Review of TA909)
Llewellyn, A., Coughlan, D., Umemneku-Chikere, C., Fulbright, H., Nevitt, S. J. & Hodgson, R., 15 Nov 2024, National Institute for Health and Care Excellence.Research output: Book/Report › Commissioned report
-
Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer
Corbett, M. S., Deng, J., Uphoff, N., Walton, M. J., Lord, J., Fulbright, H. A., Dwan, K. & Hodgson, R., 7 Feb 2024, National Institute for Health and Care Excellence.Research output: Book/Report › Commissioned report
-
Quizartinib for untreated FLT3-ITD-positive acute myeloid leukaemia: A Single Technology Appraisal
Nevitt, S. J., Llewellyn, A., Deng, J., Coughlan, D., Anwer, S., Marshall, D., Harden, M. & Hodgson, R., 12 Jun 2024, National Institute for Health and Care Excellence.Research output: Book/Report › Commissioned report
-
2023
Ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma
Llewellyn, A., Murphy, P. J., Beresford, L., Walton, M. J., Fulbright, H. A., Harden, M., Eastwood, A. J. & Hodgson, R., 17 May 2023, National Institute for Health and Care Excellence.Research output: Book/Report › Commissioned report
-
Cipaglucosidase alfa with miglustat for treating Pompe disease
Wade, R., Deng, J., Dwan, K., Robertson, L., Uphoff, N., Fulbright, H. A., Dias, S., Hodgson, R. & Eastwood, A. J., 15 Aug 2023, National Institute for Health and Care Excellence.Research output: Book/Report › Commissioned report
-
Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer
Walton, M. J., Corbett, M. S., Dwan, K., Njoroge, M. W., Fulbright, H. A., Uphoff, N., Hodgson, R. & Dias, S., 11 May 2023, National Institute for Health and Care Excellence.Research output: Book/Report › Commissioned report
-
Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer
Walton, M. J., Corbett, M. S., Njoroge, M. W., Beresford, L., Harden, M., Hodgson, R. & Dias, S., 9 Feb 2023Research output: Book/Report › Commissioned report
-
Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer (Rapid Review of TA885)
Walton, M. J., Rodgers, M., Fulbright, H. A., Eastwood, A. J. & Hodgson, R., 13 Dec 2023, National Institute for Health and Care Excellence.Research output: Book/Report › Commissioned report
-
Pembrolizumab with chemotherapy for treating recurrent, persistent or metastatic cervical cancer [ID3798]Pembrolizumab with chemotherapy for treating recurrent, persistent or metastatic cervical cancer
Rodgers, M., Walton, M. J., Anwer, S., Corbett, M. S., Njoroge, M. W., Fulbright, H. A., Naik, R., Powell, M., Eastwood, A. J. & Hodgson, R., 29 Mar 2023, National Institute for Health and Care Excellence.Research output: Book/Report › Commissioned report
-
2022
Asciminib for chronic myeloid leukaemia after two or more tyrosine kinase inhibitors
Murphy, P. J., Llewellyn, A., Meader, N., Hodgson, R. & Simmonds, M. C., 3 Aug 2022, National Institute for Health and Care Excellence.Research output: Book/Report › Commissioned report
-
Devices for remote continuous monitoring of people with Parkinson’s disease: A Diagnostics Assessment Report for the National Institute for Health and Care Excellence
Cox, E. M., Wade, R., Hodgson, R., Fulbright, H. A., Phung, H., Meader, N., Walker, S. M., Rothery, C. & Simmonds, M. C., 2022, National Institute for Health and Care Excellence.Research output: Book/Report › Commissioned report
-
OTL-200 for treating metachromatic leukodystrophy
Walton, M. J., Corbett, M. S., Melton, H. A., Claxton, L., Harden, M., Hodgson, R. & Simmonds, M. C., 28 Mar 2022, National Institute for Health and Care Excellence.Research output: Book/Report › Commissioned report
-
2021
Baricitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis
Hodgson, R., Sharif, S., Beresford, L., Anwer, S., Walton, M. J., Wittmann, M., Harden, M., Khouja, C. L. & Dias, S., 3 Mar 2021, National Institute for Health and Care Excellence.Research output: Book/Report › Commissioned report
-
2020
Entrectinib for treating NTRK fusion-positive solid tumours
Hodgson, R., Llewellyn, A., Murphy, P. J., Claxton, L., Beresford, L., Walton, M. J., Glynn, D., Wright, K. & Dias, S., 12 Aug 2020, National Institute for Health and Care Excellence.Research output: Book/Report › Commissioned report
-
Galcanezumab for preventing migraine
Meader, N., Murphy, P. J., Dias, S., Wright, K. & Hodgson, R., 18 Nov 2020, National Institute for Health and Care Excellence.Research output: Book/Report › Commissioned report
-
2019
Cerliponase alfa for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2)
Walton, M. J., O'Connor, J., Meader, N., Claxton, L., Harden, M., Woolacott, N. F. & Hodgson, R., 27 Nov 2019, National Institute for Health and Care Excellence.Research output: Book/Report › Commissioned report
-
Certolizumab pegol for treating moderate to severe plaque psoriasis
Walton, M. J., Sharif, S., Claxton, L., Wade, R., Hodgson, R., Harden, M. & Eastwood, A. J., 17 Apr 2019, National Institute for Health and Care Excellence.Research output: Book/Report › Commissioned report
-
Letermovir for the prophylaxis of cytomegalovirus reactivation or disease in people with seropositive-cytomegalovirus who have had an allogeneic haematopoietic stem cell transplant
Hodgson, R., O'Connor, J., Walton, M. J., Biswas, M. & Woolacott, N. F., 31 Jul 2019, National Institute for Health and Care Excellence.Research output: Book/Report › Commissioned report
-
2018
Ceritinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Claxton, L., Woolacott, N. F., O'Connor, J., Wright, K. & Hodgson, R., 24 Jan 2018, National Institute for Health and Care Excellence.Research output: Book/Report › Commissioned report
-
Gemtuzumab ozogamicin for untreated acute myeloid leukaemia
Wade, R., Claxton, L., Walker, R. A. E., Altunkaya, J., Soares, M. O., Wright, K., Hodgson, R., Simmonds, M. C. & Palmer, S. J., 14 Nov 2018, National Institute for Health and Care Excellence.Research output: Book/Report › Commissioned report
-
Liposomal cytarabine and daunorubicin for untreated acute myeloid leukaemia
Claxton, L., Llewellyn, A., Biswas, M., Hodgson, R., Stewart, L., Harden, M. & Wade, R., 19 Dec 2018, National Institute for Health and Care Excellence.Research output: Book/Report › Commissioned report
-
Midostaurin for untreated acute myeloid leukaemia
Hodgson, R., Biswas, M., Mebrahtu, T., Morgan, P. J., Harden, M. & Woolacott, N. F., 13 Jun 2018, National Institute for Health and Care Excellence.Research output: Book/Report › Commissioned report
-
Tisagenlecleucel-T for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years
Walton, M. J., Sharif, S., Claxton, L., Wright, K., Hodgson, R. & Simmonds, M. C., 21 Dec 2018, National Institute for Health and Care Excellence.Research output: Book/Report › Commissioned report
-
2017
Eliglustat for treating type 1 Gaucher disease
Hodgson, R., Morgan, P. J., Yang, H., Hodkinson, A., Harden, M. & Woolacott, N. F., 28 Jun 2017, National Institute for Health and Care Excellence.Research output: Book/Report › Commissioned report
-
Etirinotecan pegol for treating breast cancer with brain metastases
Claxton, L., Wade, R., Sharif, S., Harden, M., Woolacott, N. F. & Hodgson, R., 11 Jul 2017, National Institute for Health and Care Excellence.Research output: Book/Report › Commissioned report
-
Ustekinumab for treating moderately to severely active CD after prior therapy
Hodgson, R., Biswas, M., Mebrahtu, T., Walton, M. J., Harden, M. & Woolacott, N. F., 12 Jul 2017, National Institute for Health and Care Excellence.Research output: Book/Report › Commissioned report
-
2016
Crizotinib for untreated anaplastic lymphoma kinase-positive non-small-cell lung cancer
Hodgson, R., Biswas, M., Morgan, P. J., Mebrahtu, T., Harden, M. & Woolacott, N. F., 28 Sept 2016, National Institute for Health and Care Excellence.Research output: Book/Report › Commissioned report
-
Ruxolitinib for disease-related splenomegaly or symptoms in adults with myelofibrosis (review of TA289)
Hodgson, R., Wade, R., Biswas, M., Harden, M. & Woolacott, N. F., 23 Mar 2016, National Institute for Health and Care Excellence.Research output: Book/Report › Commissioned report
-
2015
Communicating the benefits and risks of ultraviolet light to the general population: effectiveness and cost-effectiveness review.
Fitzgerald, A., Cikalo, M., Lethaby, A., Mahon, J., Hodgson, R., Brown, S., Patterson, J., Sreekanta, A., Burley, V., Wood, H., Edwards, M. & Glanville, J., 2015, National Institute for Health and Clinical Excellence.Research output: Book/Report › Commissioned report
-
‘Communicating the benefits and risks of ultraviolet light to the general population: cost effectiveness model technical report
Hodgson, R., Carpenter, I., Jenks, M., Dickinson, S. & Taylor, M., 2015, National Institute for Health and Clinical Excellence.Research output: Book/Report › Commissioned report